ADXN vs. LPCN, FBIO, XLO, UNCY, PMN, BOLT, RNXT, VIRX, IPA, and APM
Should you be buying Addex Therapeutics stock or one of its competitors? The main competitors of Addex Therapeutics include Lipocine (LPCN), Fortress Biotech (FBIO), Xilio Therapeutics (XLO), Unicycive Therapeutics (UNCY), ProMIS Neurosciences (PMN), Bolt Biotherapeutics (BOLT), RenovoRx (RNXT), Viracta Therapeutics (VIRX), ImmunoPrecise Antibodies (IPA), and Aptorum Group (APM). These companies are all part of the "pharmaceutical preparations" industry.
Addex Therapeutics (NASDAQ:ADXN) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, community ranking, media sentiment and analyst recommendations.
Addex Therapeutics has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Comparatively, Lipocine has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500.
16.1% of Addex Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by company insiders. Comparatively, 6.1% of Lipocine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Lipocine has a net margin of 0.00% compared to Addex Therapeutics' net margin of -644.66%. Lipocine's return on equity of -37.62% beat Addex Therapeutics' return on equity.
Lipocine received 331 more outperform votes than Addex Therapeutics when rated by MarketBeat users. Likewise, 70.14% of users gave Lipocine an outperform vote while only 46.15% of users gave Addex Therapeutics an outperform vote.
Addex Therapeutics has higher revenue and earnings than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Addex Therapeutics had 1 more articles in the media than Lipocine. MarketBeat recorded 5 mentions for Addex Therapeutics and 4 mentions for Lipocine. Addex Therapeutics' average media sentiment score of 1.43 beat Lipocine's score of 1.11 indicating that Addex Therapeutics is being referred to more favorably in the media.
Summary
Addex Therapeutics beats Lipocine on 8 of the 15 factors compared between the two stocks.
Get Addex Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Addex Therapeutics Competitors List
Related Companies and Tools
